Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14142MR)

This product GTTS-WQ14142MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Atherosclerosis&Acute coronary syndrome (ACS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14142MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10772MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ4393MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ12983MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ9443MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ2004MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGT-181
GTTS-WQ10046MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ7139MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ2465MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 181
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW